Publications by authors named "ChanHo Na"
Article Synopsis
- Mesenchymal stem cells (MSCs) have potential in medical therapies due to their ability to modulate immune responses, and this study focused on their use in treating atopic dermatitis (AD).
- A phase 1 trial confirmed the safety of allogenic human bone marrow-derived clonal MSCs (hcMSCs) in patients, leading to a phase 2 trial that showed hcMSC treatment resulted in improved eczema severity after 12 weeks compared to a placebo.
- Despite some mild adverse effects, hcMSC therapy had an acceptable safety profile, suggesting it could be effective, though further extensive research is needed to validate these initial findings.
Atopic dermatitis (AD) is a chronic inflammatory skin disease that is characterized by complex pathophysiology involving both skin barrier dysfunction and aberrant type 2 inflammation/immune responses. AD can be a debilitating condition that drastically impairs quality of life, especially in patients with moderate-to-severe disease. Currently, topical therapies such as corticosteroids and non-steroidal immunomodulatory therapy provide limited efficacy for patients with moderate-to-severe AD; limitations include inadequate response, cutaneous toxicity from overuse, and poor tolerance due to stinging and burning.
View Article and Find Full Text PDF